Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.68 |
| ▸ | CA2 | P00918 | 12/20 | 0.68 |
| ▸ | CA9 | Q16790 | 12/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA3 | P07451 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA6 | P23280 | 1/20 | 0.68 |
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.68 |
| ▸ | LPL | P06858 | 7/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25303649 | 0.86 | CA1 (0.66) | CA1CA2CA9CA12CA3 | |
| SCHEMBL190423 | 0.82 | CA1 (0.73) | CA1CA2CA9CA12CA3 | |
| SCHEMBL1494640 | 0.80 | CA1 (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL24133598 | 0.79 | CA1 (0.69) | CA1CA2CA9CA12CA3 | |
| SCHEMBL4376225 | 0.78 | LIPG (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL10214999 | 0.78 | CA1 (0.68) | CA1CA2CA9CA12CA3 | |
| SCHEMBL2415277 | 0.78 | CA1 (0.68) | CA1CA2CA9CA12CA3 | |
| SCHEMBL23731226 | 0.77 | CA1 (0.42) | CA1CA2CA9CA12CA3 | |
| SCHEMBL38655884 | 0.77 | CA2 (0.66) | CA1CA2CA9CA12CA3 | |
| SCHEMBL20523561 | 0.76 | CA1 (0.41) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494995-B2 | Phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20060258671-A1 | Phenylpyridylpiperazine compounds | LES LABORATORIES SERVIER (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1721896-A1 | Phenylpyridinylpiperazin derivatives, the process to make them and the compositions containing them | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258671-A1 | Phenylpyridylpiperazine compounds | HRH4, HRH3, HRH2 | CA1 3410/4885CA2 2295/4885CA9 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.